 Invest. 1995. 96:401-410.) 
Introduction
The accelerated proliferation of glomerular mesangial cells (MC)' is a common feature of the many glomerular diseases (1) (2) (3) . The cell cycle of MC is under the influence of a large number of humoral autocrine and/or paracrine factors which either promote or suppress mitogenesis and cell proliferation (1) (2) (3) (4) . In certain glomerulopathies some of these autocrine factors are produced in high quantity by stimulated MC (1) (2) (3) (4) . Moreover, in the case of infiltrative glomerular lesions, large quantity of mitogens are also generated by invading inflammatory cells (1, 3, 5) . Understanding of the signal transduction systems by which these humoral factors modulate the rate of MC proliferation is essential for rational design of novel pharmacotherapeutic approaches aimed to suppress the excessive proliferation of MC in glomerular diseases.
Recent observations established that some growth factors and cytokines stimulate the mitotic synthesis of DNA and cell proliferation by activation of the so-called mitogen-activated protein kinase (MAPK) phosphorylation cascade (6, 7) . This signaling pathway (details of which are outlined in recent reviews) (6-10) is initiated by mitogen binding to its receptor, tyrosine phosphorylations, which is followed by interactions of "small adaptor proteins" which promote conversion of membrane-anchored Ras-GDP to active form Ras-GTP (11, 12 ). Active Ras-GTP then promotes translocation of a protooncogene-coded protein Raf-1 from cytoplasm to the membrane, which results in activation of the protein kinase moiety of Raf-l (13) . The Raf-l is first the protein kinase (6, 7, 9) which activates by phosphorylation another protein kinase (MEK or MAPKK), which in turn ultimately activates the key enzyme of the cascade the mitogen activated protein kinase (MAPK) . Then, activation of Raf-1 protein kinase initiates a sequence of protein phosphorylations which ultimately leads to activation of MAPK, which then triggers mitotic DNA synthesis and initiates the cell replication cycle (6, 7, 10) , via proline-directed phosphorylation of nuclear transcription factors of immediate early genes (9) .
Several investigators found recently that in some cell types the mitogen-activated MAPK phosphorylation cascade and stimulation of cell proliferation by growth factors/cytokines can be inhibited by "crosstalk" with another signaling system (12, (14) (15) (16) (17) the cAMP-activated protein kinase (PKA). According to current evidence, when cAMP-activated PKA phosphorylates Ser43 in the regulatory domain of the Raf-1 molecule (16) , the protein kinase activity in the catalytic domain of Raf-1 is inhibited. Since Raf-1 protein kinase initiates the whole cascade of phosphorylations, its inhibition ultimately prevents activation of MAPK and inhibits mitogenesis (11) (12) (13) (14) (15) (16) (17) . In studies of nonrenal cell types (12) the cAMP-PKA pathway was activated by potent stimuli of adenylate cyclase such as forskolin ( 14) or cholera toxin ( 15), or by high doses of hormonal agonists of adenylate cyclase (15). All of these stimuli of adenylate cyclase caused considerable accumulation of cAMP which, in turn, elicited marked inhibition of proliferation of smooth muscle cells (14) , adipocytes (15), or of fibroblasts (16, 17) . However, in a number of other cell types, such as PC12 cell line of neural origin (18) , thyroid cells, and others ( 19) , the enhanced levels of cAMP stimulated rather than inhibited activity of MAPK and promoted cell growth and differentiation ( 18, 19) .
In our preceding study of isolated rat glomeruli we observed that antagonists of some isozymes of cyclic-3',5'-nucleotide phosphodiesterases (PDE),2 mainly PDE-IV (22) , in very low concentrations suppress the generation of endogenous reactive oxygen metabolites via activation of PKA but without measurable increase in cAMP content. These observations suggested to us that decreased turnover of a cAMP pool, which is controlled by a specific PDE isozyme(s), can activate cAMP-PKA pathway without stimulation of adenylate cyclase and without significant change of measurable cAMP content (22) .
In view of these observations (22) Assay for cAMP. The MC were incubated with test agents in 24-well plates for 60 min (see Fig. 3 ), or for 16 h as in the [3H] thymidine incorporation experiments. The incubation was terminated by adding 5% TCA (final concentrations) to the wells, cells scraped, and the mixture was incubated on ice for 0.5 h. The TCA was extracted with water-saturated ether and the cAMP content was measured using radioimmunoassay (RIA) as previously described (22, 23 (23) . In experiments when cytosol and total membrane fractions were separated, cells were homogenized similarly, except that 0.3 M sucrose was added and 0.1% Triton-X-100 was omitted from the homogenization medium. The homogenates were centrifuged at 60 min at 10' g and the pellet was resuspended in the same medium, centrifugation repeated; first and second supernatants were combined and constituted the total soluble fraction or "cytosol." The washed second pellet was resuspended again in a medium of the same composition but with 0.1% Triton X-100 and without sucrose, centrifuged for (26, 30) . In experiments examining the activity of Ca2 -calmodulin-dependent PDEs, the reaction mixture also contained 2.01 mM CaCl2, to obtain 10 11M Ca2+, and 10 nog/ml of calmodufin (CaM). The PDE activity in aliquots incubated without Ca2" and CaM (but with 2 mM EGTA, vide supra) was determined as a basal activity (26, 30) . PDE-Hl and PDE-IV activities were determined as cAMP-PDE inhibitable by 3 JIM cilostamide or rolipram, respectively, as in our preceding studies (22, 23 (22, 23) .
Measurement of cAMP-dependent protein kinase (PKA) activity in situ. We used a method described by Corbin et al. (25) as in our previous study (22) with minor modifications. Quiescent MC cultures in (diameter 6 cm) Petri dishes were incubated either without added agents (controls), or with PDE isozyme inhibitors for 60 min to assure penetration of compounds into cells, or with forskolin for 10 min. The incubation was terminated by chilling the plate to 0-40C and quickly scraping the cells which were then pelleted by centrifugation at 2,500 g for 5 min at 0-40C. The supernatant was discarded and the packed MC were homogenized in a medium containing (final concentrations): 0.25 M sucrose, 0.5 mM 3-isobutyl, l-methylxanthine, 4 mM EDTA, and 20 mM MES-NaOH, pH 6.8. The homogenate was centrifuged at 27,000 g for 30 min at 0-40C. The PKA activity was measured in the supernatant by the incorporation of 32P-y-ATP into the oligopeptide Kemptide (25, 26) . The MC extract was incubated in a mixture (final concentrations): 10 j1M 32P-y-ATP (1 juCi), 0.4 mM EGTA, 0.1 mM EDTA, 8 mM NaF, 0.6 mg/ml BSA, 160 iM "Kemptide" 20 mM MES-NaOH, (pH 6.8) either with or without 1 ,.M added cAMP, and 2 jig of protein extract per tube. The incubation was carried out for 6 min at 30C, and stopped by placing the incubation mixture on 2 X 2 cm2 phosphocellulose papers (Whatman P 81) which were then immersed into 10 mM NaJ'207 in 1% H3PO4. The papers were then washed (3 x 15 min) in 1% H3PO4 dried and 32p was determined by liquid scintillation counting. Used PDE isozyme inhibitors did not interfere with PKA assay (22) . The PKA activity was assayed in one aliquot without cAMP, another aliquot with 1 jLM cAMP (maximum stimulatory dose), and also in aliquot with 1 tiM cAMP plus maximum inhibitory dose (10 ,M) of a specific PKA oligopeptide inhibitor WTPTIDE (22, 26) . The difference between PKA activity without and with 10 ILM WIPITIDE was taken as specific PKA activity, the residual protein kinase activity in the presence of WJFJ7DE was subtracted (22) . In situ activity of PKA was determined as a ratio of PKA activity measured without added cAMP (-cAMP) to total PKA activity measured with 1 1AM cAMP (+cAMP) and expressed as (-cAMP/+cAMP) PKA activity ratio (22, 25 The MC were incubated either with 10 MM forskolin or with 1 mM dibutyryl cAMP (B2cAMP) without addition of PDE inhibitors (Fig. 2, A and B) , or with cAMP-PDE isozyme inhibitors, but without stimulants of adenylate cyclase ( levels in MC more than 10-fol [3H] thymidine incorporation isozyme-specific inhibitors 10 10 MM zardaverine (PDE-III/ corporation to a similar degree in a contrast to forskolin, with content ( Fig. 2, A (Tables I and II ), inspite that PDE-IV activity in MC is about twofold higher than PDE-Ifl (Fig. 1, upper <'0.001 (7) +5±3 N.S.
(6) -44+6%11 < 0.001 (7) +7±4 N.S.
Rolipram (3 AM) (6) -20±5% § < 0.02 (7) +9±5 N.S.
(6) -24±6%1 < 0.02 (7) +8±3 < 0.05 Zardaverine (3 , (Fig. 3) than rolipram, in situ activation of PKA by cilostamide was only slightly higher than with rolipram (Fig. 3) . This comparison rises the possibility that the actions of PDE-lI and PDE-IV upon cAMP metabolism in MC may be functionally compartmentalized. Therefore, we compared effects of cilostamide and rolipram upon cAMP accumulation in MC when cAMP synthesis was enhanced by forskolin, a nonspecific stimulator of adenylate cyclase. In the presence of forskolin rolipram enhanced cAMP accumulation by 10-100-fold (Table III) , whereas cilostamide in equimolar concentrations barely affected cAMP content (increase about A + 37%) and this effect was significant only with 3 ,uM forskolin under ambient conditions (Table III A) . Since cilostamide is a much more potent inhibitor of mitogenesis than rolipram (Tables I and II and Fig. 3) these observations do suggest a special relationship between cAMP pool metabolized by PDE-III and regulation of mitogenesis.
MAPK activity. To discern whether PDE-isozyme antagonists inhibited mitogenesis as proposed (Introduction) the activity of MAPK was determined. In MC incubated with EGF the MAPK activity was about threefold enhanced (Fig. 4) . The incubation in the presence of PDE antagonists, cilostamide with rolipram, a treatment which increased cAMP (Fig. 3) , stimulated in situ activity of PKA (A + 188±48%) and inhibited mitogenesis (Fig. 3, lower panel) , resulted in a significant decrease of MAPK activity, both in the ambient state and when stimulated by EGF (Fig. 4) . The relative (-A%) inhibition of MAPK by PDE isozyme antagonists was similar in ambient and EGF stimulated states (Fig. 4) . Finally, we explored the effects of PDE isozymes inhibitors upon MC stimulated by another cytokine, PDGF. Incubation with 10 jiM cilostamide suppressed markedly (A% -69±11; n = 3; P < 0.05) mitogenesis in MC stimulated with 10 ng/ mean±SEM; n = 3, P < .01) or stimulated by 1 ng/ml PDGF (A-67±4%, mean±SEM; n = 3, P < .01); forskolin had similar inhibitory effect as in EGF-stimulated MC (data not shown).
Discussion
Present observation that forskolin and B2cAMP inhibit mitogenesis in MC, as assessed by [3H]thymidine incorporation (35, 36) , indicates that in MC the negative "crosstalk" (12) between mitogen-activated protein phosphorylation cascade pathway and the cAMP-PKA pathways does exist ( 12, (14) (15) (16) (17) . The inhibitory input of the activated cAMP-PKA pathway is very effective since it suppresses [3H]thymidine incorporation both in the ambient state (Figs. 2 and 3) as well as when MC are under stimulation of potent mitogens EGF or PDGF. MC, more than any other resident cell type populating glomerulus are site of production of growth factors and cytokines (1) (2) (3) (4) . Therefore, MC when grown in vitro are most likely exposed to autocrine/paracrine effects of endogenously synthetized mitogens. On the other hand, cells incubated with added high doses of EGF or PDGF will presumably approximate the situation of MC in immuno-inflammatory glomerular diseases, when both stimulated glomerular cells-produce endogenous mitogens at a higher rate (2) (3) (4) and are, in addition, exposed to a large quanta of cytokines produced by neutrophils and other infiltrating inflammatory cells (5) .
Guided by our recent findings that cAMP-PKA pathway in (12, (14) (15) (16) (17) . Indeed, a specific antagonists of PDE-Il, "hybrid" antagonist of PDE-IH and PDE-IV and, to a much lesser degree antagonists of PDE-IV (Tables I and II) (Fig. 2, 3 ) suppressed, in micromolar concentrations, mitogenesis of MC, both in the ambient state and when stimulated by cytokines (Tables I and II) . The pattern of PDE isozymes found in MC differs from whole rat glomeruli (22) in that PDE-ll, which is abundant in whole glomeruli is not detectable in MC, and that PDE-IV is about two times higher than PDE-llI (Fig. 1) . Neither in glomeruli (22) nor in cultured MC does PDE-I hydrolyze cAMP, and accepts only cGMP (Fig. 1 (Fig. 1) .
The antagonist of PDE-III cilostamide and also PDE-lIh/IV antagonist zardaverine suppressed [3H] thymidine incorporation to a similar degree as forskolin or B2cAMP (Fig. 2 ) but unlike forskolin, achieved this effect without measurable increases of cAMP (Table I, Fig. 2 ). This observation indicates that decreased cAMP hydrolysis by isozyme PDE-lI alone, without stimulation of adenylate cyclase, is sufficient to activate PKA in situ (Fig. 3) and to inhibit mitogenesis (Tables I and II and Fig. 3 ). Inhibition of mitogenesis can be achieved without increase of cAMP (Table I , Fig. 2 and 3 ) and this may suggest that cAMP increases only within a specific compartment of the MC that is needed for activation of PKA that is required for inhibition of [3H]thymidine incorporation (Fig. 3) . Evidence that intracellular cAMP levels are indeed increased in response to PDE-III inhibitors without detecting change of total cAMP content is provided by in situ activation of PKA (Fig. 3) .
In situ activation of PKA (25) or increased occupancy of its regulatory subunits (37) are more sensitive indices of enhanced intracellular cAMP (or its redistribution), than measurement cAMP content in the cell extracts (22, 25, 37 (Tables I and II ; Fig. 3 ).
Incubation of MC with cilostamide also activated PKA in situ to significantly higher degree than with rolipram (Fig. 3 ). Yet, when the rate of cAMP synthesis in MC is stimulated by nonspecific agonist forskolin (Table III) (40) . However, it should be also considered that in situ PDE-IV may have lower affinity for cAMP than PDE-III. The notion that a specific cAMP pool metabolized by PDE-III is linked to PKA that inhibits mitogenesis by phosphorylating Raf-l (14, 16) is also compatible with the finding that a minor increase of in situ PKA activity by cilostamide resulted in similar near-maximum inhibition of mitogenesis as the complete PKA activation by forskolin (Fig. 3) . The Raf-l protein kinase is inactivated by PKA phosphorylation of Ser43 on the inner side of the cell membrane (11, 13, 16) ; conceivably in intact MC PDE-lI may be situated close to the plasma membrane. In other cell types, for example, it is membrane-bound PDE-Ill that specifically regulates lipolysis in adipocytes (38, 39) , or contractility in cardiac sarcoplasmic reticulum (41) ; in hepatocytes, PDE-Il bound to membrane "dense vesicles" is specifically related to glucagon and insulin actions (42) . In order to detect sometimes fragile association with membrane, a very gentle cell disruption and fractionation ought to be employed (43) . Thus, the precise localization of PDE-Ill within MC needs to be determined in future specifically designed studies.
Stimulation of MAPK activity in MC by EGF affirms the identity of the assayed protein kinase as MAPK (Fig. 4) . Both under ambient conditions as well as when stimulated by EGF, PDE isozyme antagonists by decreased MAPK activity (Fig.  4) while PKA activity was significantly increased (Fig. 3) . These findings support the notion that PDE antagonists suppress [3H]thymidine incorporation via activation of the cAMP-PKA pathway and by inhibiting the mitogen-activated phosphorylation cascade upstream to MAPK and ultimately by decreasing the activity of MAPK (6, 12) . While the extent of MAPK inhibition was relatively modest (Fig. 4) , it should be realized that the employed assay does not distinguish between MAPK isozymes; the decrease in overall MAPK activities may reflect more extensive inhibition of one of the MAPK isozymes (10) . PKA was also activated only moderately by PDE inhibitors that suppressed mitogenesis to the same degree as forskolin, which activates PKA completely (Fig. 3) and blunts markedly activity of MAPK in MC (44) .
In conclusion, the present study shows that cAMP-PKA signaling pathway has a suppressive rather than a stimulatory effect upon MC proliferation and that the mitogen-activated phosphorylation cascade of these cells is amenable to an indirect inhibition by selective antagonists of PDE isozyme type III (and to lesser degree PDE-IV), both in the ambient state and under stimulation by mitogens. Further, we also show that in micromolar concentrations of a PDE-llI antagonist can activate in situ PKA without detectable changes in cAMP content (Fig. 3) , and moderate activation of PKA elicits near-maximum inhibition of mitogenesis, as assessed by [3H]thymidine incorporation. The pattern of findings points to the possibility that the PDE-1II-regulated cAMP pool is functionally related to PKA activation, phosphorylation and decrease in the activity of Raf-l protein kinase, which ultimately results in decrease of MAPK activity (Fig. 4) .
Previously (22) we found that a specific inhibitor of PDE-IV rolipram, via activation of PKA, attenuated formation of reactive oxygen metabolites, another important pathogenic factor causing glomerular injury. Thus, the results of the present as well as of our previous study (22) suggest that PDE isozymes in glomerular cells represent potential novel targets for pharmacologic intervention (45) which, by modulation of the signalling pathways, may block or diminish various types of pathologic processes in glomeruli.
